Clinical trial · Observational
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients
NCT00815555CI-TRIAL-00001857unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to examine whether tamoxifen-treated Israeli breast cancer patients who are CYP2D6 poor metabolizers (CYP2D6\*4/\*4 genotype) are at higher cancer relapse risk during 2.5-5-year follow-up period from initial diagnosis and primary treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| There is no intervention - this is an observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- Women diagnosed with receptor positive breast cancer, treated with Tamoxifen
- interventionNames
- Other: There is no intervention - this is an observational study
Primary outcomes (1)
- measure
- Tamoxifen efficacy for avoiding breast cancer relapse in relation to CYP2D6 genotype
Secondary outcomes (1)
- measure
- Prevalence of CYP2D6 poor metabolizers genotype in Israeli female population treated with Tamoxifen
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female * Age \> 18 * Treated with Tamoxifen following diagnosis of breast cancer Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.